Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 48 Rectal Neoplasms 29 Stomach Neoplasms 24 Colorectal Neoplasms 24 Triple Negative Breast Neoplasms 18 Neoplasm Metastasis 10 Nasopharyngeal Carcinoma 10 Colonic Neoplasms 10 Locally Advanced Rectal Cancer 7 Esophageal Neoplasms 7 Biliary Tract Neoplasms 7 Brain Neoplasms 5 Adenocarcinoma Of Esophagus 5 Adenocarcinoma 5 Pancreatic Neoplasms 4 Neoplasms 4 Gastrointestinal Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Neuroendocrine Tumors 3 HER2-positive Breast Cancer 3 Cholangiocarcinoma 3 Advanced Solid Tumors 3 Recurrence 2 Neoplasm, Residual 2 Meningeal Neoplasms 2 Locally Advanced Colorectal Cancer 2 Esophageal Squamous Cell Carcinoma 2 Early Low Rectal Cancer 2 Colorectal Cancer Metastatic 2

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Pan-tumor × Capecitabine × Clear all

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co., Ltd.

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡